Interest Expense
Alnylam Pharmaceuticals·Products & Services·2 segments
Breakdown
| Segment | Q1 '26 |
|---|---|
| Vutrisiran | $23.93M |
| Zilebesrian | $1.85M |
| Total | $23.93M |
Segments
VutrisiranView metric
ZilebesrianView metric
| Segment | Q1 '26 |
|---|---|
| Vutrisiran | $23.93M |
| Zilebesrian | $1.85M |
| Total | $23.93M |